Intra-articular injections with Carboxymethyl-Chitosan in patients affected by knee osteoarthritis non-responders to hyaluronic acid: a pilot study.

IF 1.8 Q3 MEDICINE, RESEARCH & EXPERIMENTAL European Journal of Translational Myology Pub Date : 2024-08-22 DOI:10.4081/ejtm.2024.12413
Nicola Manocchio, Concetta Ljoka, Nicolò Piacentini, Roberto Sorge, Giulia Vita, Calogero Foti
{"title":"Intra-articular injections with Carboxymethyl-Chitosan in patients affected by knee osteoarthritis non-responders to hyaluronic acid: a pilot study.","authors":"Nicola Manocchio, Concetta Ljoka, Nicolò Piacentini, Roberto Sorge, Giulia Vita, Calogero Foti","doi":"10.4081/ejtm.2024.12413","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis (OA) is a disabling disease that causes pain and functional limitation. OA symptoms can be treated with intra-articular injections of anti-inflammatory, viscosupplementary, or viscoinductive products. Non-responders to these approaches have limited options, often surgical (e.g. knee replacement). This retrospective study aims to evaluate the efficacy of a single injection of Carboxymethyl-Chitosan for advanced (Kellgren-Lawrence ≥3) and symptomatic knee OA in non-responders to hyaluronic acid. We enrolled 10 patients (5 female, 5 male). Treatment efficacy was assessed through the Visual Analogue Scale (VAS, pain) and the Knee Injury and Osteoarthritis Outcome Score (KOOS, knee function). Data are acquired from rating scales were administered at the time of injection (T0), one month (T1), three months (T2), and six months (T3) after treatment as for clinical practice. Results showed a significant improvement in pain and function at T1, with a subsequent gradual resumption of symptoms. In conclusion, the treatment showed a better outcome in the short term (i.e. up to 1 month after treatment); however, raw values of VAS and KOOS did not return to baseline levels showing a maintenance of improvement albeit not statistically significant.</p>","PeriodicalId":46459,"journal":{"name":"European Journal of Translational Myology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487637/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Translational Myology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/ejtm.2024.12413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoarthritis (OA) is a disabling disease that causes pain and functional limitation. OA symptoms can be treated with intra-articular injections of anti-inflammatory, viscosupplementary, or viscoinductive products. Non-responders to these approaches have limited options, often surgical (e.g. knee replacement). This retrospective study aims to evaluate the efficacy of a single injection of Carboxymethyl-Chitosan for advanced (Kellgren-Lawrence ≥3) and symptomatic knee OA in non-responders to hyaluronic acid. We enrolled 10 patients (5 female, 5 male). Treatment efficacy was assessed through the Visual Analogue Scale (VAS, pain) and the Knee Injury and Osteoarthritis Outcome Score (KOOS, knee function). Data are acquired from rating scales were administered at the time of injection (T0), one month (T1), three months (T2), and six months (T3) after treatment as for clinical practice. Results showed a significant improvement in pain and function at T1, with a subsequent gradual resumption of symptoms. In conclusion, the treatment showed a better outcome in the short term (i.e. up to 1 month after treatment); however, raw values of VAS and KOOS did not return to baseline levels showing a maintenance of improvement albeit not statistically significant.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对透明质酸无反应的膝关节骨关节炎患者进行羧甲基壳聚糖关节内注射:一项试点研究。
骨关节炎(OA)是一种致残性疾病,会导致疼痛和功能受限。治疗 OA 症状的方法有关节内注射消炎药、粘液补充剂或粘液诱导剂。对这些方法无反应者的选择有限,通常采用外科手术(如膝关节置换术)。这项回顾性研究旨在评估单次注射羧甲基壳聚糖对透明质酸无应答的晚期(Kellgren-Lawrence ≥3)和无症状膝关节 OA 的疗效。我们共招募了 10 名患者(5 名女性,5 名男性)。治疗效果通过视觉模拟量表(VAS,疼痛)和膝关节损伤与骨关节炎结果评分(KOOS,膝关节功能)进行评估。数据来自注射时(T0)、治疗后一个月(T1)、三个月(T2)和六个月(T3)的评分表,与临床实践一致。结果显示,T1 时疼痛和功能明显改善,随后症状逐渐恢复。总之,治疗在短期内(即治疗后 1 个月内)取得了较好的疗效;然而,VAS 和 KOOS 的原始值并未恢复到基线水平,这表明尽管没有统计学意义,但仍有改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Journal of Translational Myology
European Journal of Translational Myology MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
3.30
自引率
27.30%
发文量
74
审稿时长
10 weeks
期刊最新文献
Low level laser therapy and rheumatoid arthritis: a systematic review and meta-analysis study. Vitamin D receptor gene polymorphisms in patients with relapsing multiple sclerosis. Efficacy of electrical stimulation of the zygomaticus muscle in complete facial paralysis: evidence from facial grading and automated image analysis. Deceleration of denervated facial muscle atrophy through functional electrical stimulation: a sonographic quantification in patients with facial nerve paralysis. Obsessive-compulsive disorder, major depressive disorder, and addiction: the vicious relationship.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1